You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs i ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Speech-based biomarkers of CNS dysfunction associated with early Alzheimers disea

    SBC: KOBAK, KENNETH A            Topic: NIA

    DESCRIPTION (provided by applicant): More efficient methods to screen and monitor elderly patients in clinical practice and research are needed, but visits to clinical offices are expensive and many older patient are restricted by mobility or transportation access. The Alzheimer's Disease Cooperative Study (ADCS) is evaluating several technology platforms for remotely monitoring patient stat ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Biomarkers for Early Detection of Aspergillosis

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive aspergillosis (IA) caused by the fungus Aspergillus fumigatus is the most frequent fungal cause of death in immunocompromised patients. The number of patients at risk for developing IA is steadily increasing due to advances in medicine. Early and accurate diagnosis of IA is critical to patient outcome, yet is exceedingly difficult due to the lack of sp ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. CMV Therapeutic Vaccine for the Treatment of Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Recently, temozolomide (TMZ), a myelosuppressive alkylating chemotherapy, has shown a benefit in patients with glioblastoma multiformes (GBM), but median survival is still less than 15 months. Moreover, these conventional chemotherapies lack specificity and result in incapacitating damage to surrounding normal brain and systemic tissues. Immunotherapy may provi ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. A Quantitative Optical Sensor to Monitor Pre-Clinical Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Angiogenesis and hypoxia can significantly influence the efficacy of therapy and the behavior of surviving tumor cells. This important fact is supported by a vast amount of literature on pre-clinical models and clinical studies. There is growing demand for technologies to measure tumor hypoxia and angiogenesis temporally and spatially in vivo to enable advance ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Novel SET Antagonists for the Treatment of Chronic Myelogenous Leukemia

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Chronic Myelogenous Leukemia (CML) affects nearly 14,000 patients worldwide and is a disorder of the pluripotent hematopoietic stem cells with two distinct phases. The protracted myelopoliferative chronic phase is followed by a rapidly fatal blast crisis. In CML, a chromosomal translocation leads to production of the Philadelphia Chromosome (Ph1) in which the ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Devices enabling improved light delivery for photodynamic therapy of oral cancer

    SBC: LUCIFICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Oral cancer is a devastating disease that impacts 640,000 people worldwide. Though treatment with photodynamic therapy can be effective with significantly less morbidity than alternative therapies, problems arising fromless than optimal light delivery to the oral cavity have hindered its widespread application. The goal of the proposed research is to provide a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St

    SBC: INTICA BIOMEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This project is designed to allow independent experts in the development and/or application of in vitro breast cancer diagnostic tests, Drs. Badve (breast pathologist) and Sledge (breast oncologist), to evaluate INTICA's candidate anti-DEspR mAbs to develop the preliminary materials and methods for a commercially viable companion diagnostic test. DEspR, th ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. QuitAdvisorOB: A tool for delivering smoking cessation guidance to pregnant women

    SBC: HEALTH DECISION TECHNOLOGIES, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): The long-term objective of this project is to provide a smoking-cessation intervention tool for health care providers in prenatal settings. Smoking during pregnancy is a significant public health issue. The prevalence of smoking in women of child-bearing age generally ranges between 17 and 35 percent worldwide, and is heavily influenced by maternal age, ethnici ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government